Literature DB >> 22053676

Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.

H Işçi1, N Güdücü, A Y Basgul, K Aydinli, Z Calay, I Dünder.   

Abstract

Metastasis of extragenital neoplasms to the uterus is extremely rare. Lobular breast cancers metastasize to the uterus more than ductal carcinomas, but they metastasize as tiny nodules that can be missed with the standard diagnostic workup. Uterine involvement by a metastatic tumor is usually a manifestation of end-stage disease; patients are reported to die within weeks to months. Therefore surgery is not recommended. Here we report a case of lobular breast cancer metastasizing to a leiomyoma in a patient using letrozole. Our patient was submitted to surgery because the leiomyoma had grown to the level of the xiphoid process. She is alive one year after the operation. In conclusion growth of leiomyomas under aromatase inhibitors should be considered as a sign of metastases and surgery can be planned in selected cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22053676

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  The potential role of HER2 upregulation in metastatic breast cancer to the uterus: a case report.

Authors:  Melissa Y Y Moey; Omer A Hassan; Christos N Papageorgiou; Stephanie L Schnepp; John T Hoff
Journal:  Clin Case Rep       Date:  2016-08-23

2.  Tumor-To-Tumor Metastasis of Poorly Differentiated Gastric Carcinoma to Uterine Lipoleiomyoma.

Authors:  Ryo Kiyokoba; Hiroshi Yagi; Hideaki Yahata; Yoshiaki Kawano; Eisuke Kaneki; Kaoru Okugawa; Kenzo Sonoda; Kiyoko Kato
Journal:  Case Rep Obstet Gynecol       Date:  2015-11-25

Review 3.  Asymptomatic uterine metastasis of breast cancer: Case report and literature review.

Authors:  Dechen Kong; Xiaotong Dong; Peiyan Qin; Daqing Sun; Zhengtao Zhang; Yan Zhang; Furong Hao; Mingchen Wang
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.